CDKL5 deficiency disorder (CDD) is associated with refractory infantile onset epilepsy, global developmental delay, and variable features that include sleep, behavioral disturbances, and movement disorders. Current treatment is primarily symptom-based and informed by experience in caring for this population.
The post Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder appeared first on Society of Cannabis Clinicians.